Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent

被引:8
作者
Shang, Chuquan [1 ]
Hassan, Bardes [1 ,2 ]
Haque, Moinul [1 ]
Song, Yuqi [1 ,3 ]
Li, Jing [1 ,4 ]
Liu, Dongzhe [1 ,5 ,6 ]
Lipke, Eva [1 ,7 ]
Chen, Will [1 ]
Giuriato, Sylvie [8 ]
Lai, Raymond [1 ,9 ]
机构
[1] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2R3, Canada
[2] Cairo Univ, Fac Vet Med, Dept Pathol, Giza 12211, Egypt
[3] Jilin Univ, Norman Bethune Hlth Sci Ctr, Changchun 130021, Peoples R China
[4] Harbin Med Univ, Coll Basic Med Sci, Elect Microscopy Ctr, Harbin 150080, Peoples R China
[5] Shenzhen Univ Gen Hosp, Dept Hematol & Oncol, Shenzhen 518055, Peoples R China
[6] Harbin Med Univ, Coll Basic Med Sci, Lab Biol & Chem, Harbin 150080, Peoples R China
[7] Albstadt Sigmaringen Univ, Dept Life Sci, D-72488 Sigmaringen, Germany
[8] Univ Toulouse III Paul Sabatier, CRCT, INSERM U1037, CNRS ERL5294, F-31037 Toulouse, France
[9] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2R3, Canada
关键词
autophagy; ALK plus ALCL; cancer stem-like cells; MYC; crizotinib; chloroquine; resistance;
D O I
10.3390/cancers13020181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Autophagy is a cell survival and recycling mechanism which protects cancer cells upon therapeutic drug treatment. Here we investigated the impact of autophagy inhibition in a cancer of lymphoid origin, namely ALK-positive anaplastic large cell lymphoma (ALK + ALCL). We inhibited autophagy in two distinct cell subsets of ALK + ALCL, one of which we previously shown to possess more stem-like and tumorigenic properties. Our study found that blockage of autophagy in the stem-like subset resulted in marked drug-sensitization to crizotinib, a current therapeutic agent used to treat ALK + ALCL. We also found differential involvement of the Myconcogene in the autophagy process within the two subsets and identified its relative importance to the stem-like population. Our research suggests inhibition of autophagy alongside crizotinib preferentially targets stem-like cells, thus improving crizotinib therapy. Previously it was shown that autophagy contributes to crizotinib resistance in ALK-positive anaplastic large cell lymphoma (ALK + ALCL). We asked if autophagy is equally important in two distinct subsets of ALK + ALCL, namely Reporter Unresponsive (RU) and Reporter Responsive (RR), of which RR cells display stem-like properties. Autophagic flux was assessed with a fluorescence tagged LC3 reporter and immunoblots to detect endogenous LC3 alongside chloroquine, an autophagy inhibitor. The stem-like RR cells displayed significantly higher autophagic response upon crizotinib treatment. Their exaggerated autophagic response is cytoprotective against crizotinib, as inhibition of autophagy using chloroquine or shRNA against BECN1 or ATG7 led to a decrease in their viability. In contrast, autophagy inhibition in RU resulted in minimal changes. Since the differential protein expression of MYC is a regulator of the RU/RR dichotomy and is higher in RR cells, we asked if MYC regulates the autophagy-mediated cytoprotective effect. Inhibition of MYC in RR cells using shRNA significantly blunted crizotinib-induced autophagic response and effectively suppressed this cytoprotective effect. In conclusion, stem-like RR cells respond with rapid and intense autophagic flux which manifests with crizotinib resistance. For the first time, we have highlighted the direct role of MYC in regulating autophagy and its associated chemoresistance phenotype in ALK + ALCL stem-like cells.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 37 条
  • [1] Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
    Mitou, Geraldine
    Frentzel, Julie
    Desquesnes, Aurore
    Le Gonidec, Sophie
    AlSaati, Talal
    Beau, Isabelle
    Lamant, Laurence
    Meggetto, Fabienne
    Espinos, Estelle
    Codogno, Patrice
    Brousset, Pierre
    Giuriato, Sylvie
    ONCOTARGET, 2015, 6 (30) : 30149 - 30164
  • [2] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Ganesan, Prasanth
    Joshua, Thanda
    Sundersingh, Shirley
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 353 - 354
  • [3] Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib
    Prasanth Ganesan
    Thanda Joshua
    Shirley Sundersingh
    Tenali Gnana Sagar
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 353 - 354
  • [4] Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics
    Meurillon, Roxane
    Leruste, Amaury
    BULLETIN DU CANCER, 2023, 110 (03) : 250 - 251
  • [5] Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma
    Shang, Chuquan
    Lai, Justine
    Haque, Moinul
    Chen, Will
    Wang, Peng
    Lai, Raymond
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [6] Identification and Characterization of Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma Using the SORE6 Reporter
    Li, Jing
    Haque, Moinul
    Shang, Chuquan
    Hassan, Bardes
    Liu, Dongzhe
    Chen, Will
    Lai, Raymond
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2021, 43 (02) : 543 - 557
  • [7] Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition
    Kim, Dongchan
    Koh, Youngil
    Yoon, Sung-Soo
    ANTICANCER RESEARCH, 2020, 40 (03) : 1395 - 1403
  • [8] Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
    Harrer, Dennis Christoph
    Menhart, Karin
    Mayer, Stephanie
    Herr, Wolfgang
    Reichle, Albrecht
    Vogelhuber, Martin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [9] Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin
    Nakai, Ritsuko
    Fukuhara, Suguru
    Maeshima, Akiko Miyagi
    Kim, Sung-Won
    Ito, Yuta
    Hatta, Shunsuke
    Suzuki, Tomotaka
    Yuda, Sayako
    Makita, Shinichi
    Munakata, Wataru
    Suzuki, Tatsuya
    Maruyama, Dai
    Izutsu, Koji
    CLINICAL CASE REPORTS, 2019, 7 (12): : 2500 - 2504
  • [10] Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
    Valeria Mahuad, Carolina
    Vicente Reparaz, Maria de los Angeles
    Zerga, Marta E.
    Florencia Aizpurua, Maria
    Casali, Claudia
    Garate, Gonzalo
    RARE TUMORS, 2016, 8 (02) : 88 - 89